Prostate Cancer PD: What effect does enzalutamide have on the fatigue of prostate cancer patients?

Throughout the course of prostate cancer, the experiences of different patients are different.
As the disease progresses to metastasis (m) castration-resistant prostate cancer (CRPC), symptoms will also worsen
.

One of the main symptoms reported by prostate cancer patients is fatigue, which may be caused by the disease itself, treatment, and advanced age

One of the main symptoms reported by prostate cancer patients is fatigue, which may be caused by the disease itself, treatment, and advanced age.

Recently, researchers from Belgium published an article in "Prostate Cancer PD", using four enzalutamide-placebo controlled trials (ARCHES (NCT02677896), PROSPER (NCT02003924), PREVALIL (NCT01212991) and AFFIRM (NCT00974311)) The results reported by patients in the medium, assessing the effect of enzalutamide on patient-reported fatigue
.

Using patient-reported results from four enzalutamide-placebo-controlled trials (ARCHES (NCT02677896), PROSPER (NCT02003924), PREVALIL (NCT01212991), and AFFIRM (NCT00974311)), the fatigue reported by enzalutamide on patients was evaluated The impact of enzalutamide-placebo-controlled trials (ARCHES (NCT02677896), PROSPER (NCT02003924), PREVALIL (NCT01212991), and AFFIRM (NCT00974311)) were used to evaluate enzalutamide's reported effects on patients.
The effect of fatigue

In each study, researchers used the cancer treatment function evaluation scale-prostate item GP1 to assess fatigue at baseline, at 13 or 17 weeks, and every 12 weeks thereafter, until the disease progressed
.

The results of the study found that patients with advanced disease (metastatic and/or castration-resistant prostate cancer (CRPC)) and those who have been treated have a higher fatigue rate at baseline; the fatigue rate of PROSPER (non-metastatic CRPC) 58%, the fatigue rate of AFFIRM (metastatic CRPC after docetaxel treatment) was 86%

Proportion of patients’ fatigue deterioration or improvement

Proportion of patients’ fatigue deterioration or improvement

In summary, the degree of fatigue is higher in mCRPC and lower in the early stages of the disease
.

At 13-17 weeks after the start of enzalutamide or placebo treatment, fatigue was increased, while enzalutamide treatment was higher, and stabilized or improved thereafter

The degree of fatigue is higher in mCRPC and lower in the early stages of the disease

Original source:

Bertrand F Tombal, Stephen J Freedland, Andrew J Armstrong et al.

Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials

 

Leave a message here